SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downwards as the broader crypto market experiences a pullback, sparking discussions about potential support levels and whether this is a temporary dip or a longer-term correction. The community is debating the influence of large holders and potential market manipulation, while also considering historical patterns and future catalysts. Some traders are expressing concern and urging caution, while others see this as a buying opportunity.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending downwards as the community debates whether recent drops are a market correction or the start of a longer-term decline, with some citing strong earnings and jobs data as reasons for potential bounces. Concerns around AI's impact and comparisons to past market downturns are fueling bearish sentiment, while others anticipate a rally into the holiday season. Traders are closely watching key support levels and VIX for potential market direction cues.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending downwards as the community expresses concerns over its large Ethereum holdings amidst a broader crypto downturn, with many pointing to unrealized losses and the potential impact of upcoming earnings. Discussions revolve around the company's strategy, particularly regarding staking, and whether CEO Tom Lee can address investor anxieties. Some traders speculate on coordinated short attacks, while others see a buying opportunity if the company starts staking.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amid a sharp market reversal driven by concerns about future rate cuts and disappointing reactions to tech earnings, sparking community discussion on potential support levels and market manipulation. Community members are debating whether this is a temporary pullback or the start of a larger correction, with some pointing to potential negative catalysts while others anticipate a bounce. Discussions also involve the impact of political factors and the unwinding of carry trades on market sentiment.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending amidst community discussion surrounding its earnings report and potential growth prospects, with some investors comparing it to Robinhood ($HOOD). Despite positive earnings, some express concerns about the overall market conditions impacting the stock, while others anticipate a potential short squeeze and future gains.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy (MSTR) is trending downwards as Bitcoin's recent volatility sparks concerns about the company's heavy investment in the cryptocurrency and potential margin calls. The community is actively discussing downside risk, potential bankruptcy scenarios, and the impact of prominent figures like Jim Cramer and Michael Saylor on the stock's future, questioning its correlation with Bitcoin's price movements.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors assess its stability amid broader market uncertainty and an upcoming earnings report, with some highlighting its potential to capture market share from competitors. The community is also discussing Walmart's AI initiatives and the impact of consumer spending trends on its performance. Additionally, Walmart's recent announcement of a CEO transition is being monitored for its potential impact on the company's strategic direction.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amid a volatile trading session, driven by reactions to increased capital expenditure plans and anticipation for Nvidia's upcoming earnings report. Community members are actively debating whether the recent pullback presents a buying opportunity or signals an overbought condition, with some citing strong fundamentals and rising memory prices, while others point to potential overvaluation and cyclical concerns within the semiconductor sector.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending as traders assess its recent pullback and potential for a rebound, with some noting its relative strength compared to tech. Community members are actively discussing key support and resistance levels, put/call flows, and the potential impact of upcoming economic data and $NVDA earnings on small caps. Overall sentiment appears mixed, with both bullish and bearish viewpoints being shared.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit ($INTU) is trending due to recent earnings reports and subsequent analyst activity, with some community members pointing to strong financial results, particularly driven by AI integration and TurboTax Live. However, there are concerns about the company's valuation and potential impact from tariffs on small businesses, creating mixed sentiment, especially regarding the AI impact on productivity for end users. The stock's price movement and future growth potential are key discussion points among investors.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Buffett's Investing Lessons: What They Mean for ETF Investors

Buffett's final lessons guide ETF investors toward discipline, cash strength and quality picks like SPY, ITOT, VTV and MINT.

<ul class="summary-bullets"><li>USA Rare Earth said that the acquisition represents a significant acceleration of its magnet-to-mine strategy, establishing an end-to-end rare earth supply chain.&nbsp;</li><li>The deal would enable LCM to continue expanding and serving its global customer base with a broad portfolio of rare earth and critical metals and alloys.</li><li>The deal comes on the heels of the Trump administration’s attempt to boost U.S. production of critical minerals and the government has invested in a few rare earth companies, including MP Materials and Trilogy Metals.</li></ul>USA Rare Earth (USAR) shares rose nearly 3% in premarket trading on Wednesday after the company announced that it had received regulatory approval from the UK Minister of State for its acquisition of LCM.The company said that it has now received the only regulatory approval required and expects to close the acquisition on time, in line with its target for the fourth quarter of calendar year 2025.<h2 class="st-heading-2">Rare Earth Push In The US</h2>The deal comes on the heels of the Trump administration’s attempt to boost U.S. production of critical minerals, and the government has invested in a few rare earth companies, including MP Materials and Trilogy Metals.The U.S. and China have also reached an agreement to ease rare-earth exports for at least a year. According to a White House Memo, China will issue general licenses valid for the export of rare earths, gallium, germanium, antimony, and graphite, benefiting U.S. end-users and their suppliers worldwide.The general license means the de facto removal of controls China imposed since 2023.<h2 class="st-heading-2">USA Rare Earth, LCM Deal</h2>USA Rare Earth said that the acquisition represents a significant acceleration of its magnet-to-mine strategy, establishing an end-to-end rare earth supply chain. The deal would enable LCM to continue expanding and serving its global customer base with a broad portfolio of rare earth and critical metals and alloys.This would also help in the supply of Neodymium Iron Boron (NdFeB) metal and strip cast alloy to USAR's Stillwater, Oklahoma magnet facility once production begins.USA Rare Earth said that LCM's metals and alloys are essential to the manufacturing of advanced magnets, semiconductors, and aerospace components. LCM supplies customers across defense, automotive, electric vehicle, industrial, and technology sectors in the U.S., UK, France, Germany, Japan, and Taiwan.Retail sentiment on USA Rare Earth remained unchanged in the ‘bearish’ territory, with message volumes at ‘low’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/USAR">Shares of USA Rare Earth</a> have gained nearly 55% this year and increased by 65% over the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-sues-global-cybercrime-ring-over-massive-smishing-campaign-report/cLPIu1eRE5Y">Google Sues Global Cybercrime Ring Over Massive Smishing Campaign: Report</a>

In this photo illustration, the USA Rare Earth logo is seen displayed on a smartphone screen.

USA Rare Earth Stock Rises After Clearing Final Regulatory Hurdle In LCM Acquisition

The company has announced that it has now received the only regulatory approval required and expects to close the acquisition on schedule, in line with its stated target for the fourth quarter of calendar year 2025.

Equity

The company has announced that it has now received the only regulatory approval required and expects to close the acquisition on schedule, in line with its stated target for the fourth quarter of calendar year 2025.


<ul class="summary-bullets"><li>Ondas said that Sentry CS has seen rapid growth, with combat-proven deployments across 25 countries, and has achieved fully operational threat mitigation.</li><li>The company expects the transaction to close in November 2025, and the terms of the deal have not been disclosed.</li><li>Last week, Ondas announced a definitive agreement to acquire a controlling interest in 4M Defense, an Israeli smart demining company specializing in advanced demining capabilities.</li></ul>Ondas Holdings Inc. (ONDS) became one of the top trending tickers on Stocktwits and the company’s shares rose 4% in early trading on Tuesday following the announcement that it has entered into a definitive agreement to acquire Sentry CS, an Israel-based company in Cyber-over-RF (CoRF) and Protocol-Manipulation counter-Unmanned Aerial Systems (UAS) technology."The addition of Sentrycs will strengthen our leadership in counter-UAS and solidify Ondas' position as a full-spectrum provider of autonomous defense solutions," said Eric Brock, Chairman and CEO of Ondas Holdings.&nbsp;Ondas expects the transaction to close in November 2025. The terms of the deal were not disclosed.Retail sentiment on Ondas jumped to ‘bullish’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Sentry CS’ Technology</h2>Ondas said that Sentry CS has seen rapid growth, with combat-proven deployments across 25 countries, and has achieved fully operational threat mitigation."Passive RF detection and tracking are essential to modern layered defense, and Sentrycs brings a proven technology platform already deployed across sensitive airspace, critical infrastructure, and border environments,” Brock said.Brock added that by integrating Sentry CS with Ondas’ Iron Drone Raider system, the company expects to deliver a unified detect-to-defeat solution that addresses the rapidly evolving threat landscape for its defense and homeland security customers worldwide.<h2 class="st-heading-2">Ondas’ Recent Slew Of Acquisitions</h2>Last week, Ondas announced a definitive agreement to acquire a controlling interest in 4M Defense, an Israeli smart demining company specializing in advanced demining capabilities, including robotic systems with terrestrial and subsurface AI-powered intelligence technologies.Ondas had noted that 4M Defense will expand Ondas Autonomous Systems’ addressable market into the large global landmine and UXOs clearance and subsurface intelligence platforms market.The company had also announced the acquisition of a controlling interest in Insight Intelligent Sensors, an Israeli developer of AI-driven electro-optical sensing systems.<a href="https://stocktwits.com/symbol/ONDS">Shares of Ondas</a> have gained over 771% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dennys-620-million-deal-oppenheimer-says-not-expecting-competitive-bidding-process/cL28guSR36a">Denny's $620 Million Deal: Oppenheimer Says Not Expecting ‘Competitive Bidding Process’</a>

In this photo illustration, a person holds a smartphone displaying the logo of Ondas Holdings Inc. 

ONDS Stock Rises Following Acquisition Of Israel-Based Sentry CS

Ondas expects the transaction to close in November 2025, and the terms of the deal have not been disclosed.

<ul class="summary-bullets"><li>The payment was in connection with the dosing of the first patient in a late-stage registrational trial of Ziftomenib.</li><li>Kura Oncology and Kyowa Kirin had entered into a deal in November 2024 to jointly develop and commercialize Ziftomenib. &nbsp;</li></ul>Kura Oncology (KURA) said on Friday that it received a $30 million milestone payment under its collaboration agreement with Japan-based Kyowa Kirin, inked late last year.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/24/3172720/35186/en/Kura-Oncology-Receives-30-Million-Development-Milestone-Payment-in-Ziftomenib-AML-Program-with-Kyowa-Kirin.html">payment</a> was in connection with the dosing of the first patient in a late-stage registrational program of Ziftomenib evaluating the drug in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed acute myeloid leukemia with certain conditions. The companies announced the launch of the said trial on September 29.The program includes two late-stage trials intended to support potential U.S. accelerated approval and full approval. The trial is expected to enroll patients at up to 200 sites worldwide.According to Kura, the late-stage program is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings.<h2 class="st-heading-2">Terms Of The Deal</h2>Kura Oncology and Kyowa Kirin had entered into a deal in November 2024 to jointly develop and commercialize Ziftomenib. Under the agreement, Kura is eligible to receive up to $1.2 billion in total milestone payments, including near-term milestone payments. &nbsp;As per the terms of the agreement, Kura will lead development, regulatory, and commercial strategy in the U.S. while Kyowa leads it outside the U.S.<a href="https://stocktwits.com/symbol/KURA">KURA shares</a> traded 6% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around KURA stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.KURA stock is up by over 4% this year but down by about 49% over the past 12 months.Read also:<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/jp-morgan-to-let-clients-use-bitcoin-ethereum-as-loan-collateral-by-year-end/cLGJVtKR3sH"> JPMorgan To Let Clients Use Bitcoin, Ethereum As Loan Collateral By Year-End: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement

The payment was in connection with the dosing of the first patient in a late-stage registrational trial of Ziftomenib.

<ul class="summary-bullets"><li>Viking on Thursday reported a third-quarter loss per share of $0.81, compared to the expected loss of $0.7 per share.&nbsp;</li><li>Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating.</li><li>The analyst noted that two of the company’s late-stage trials for subcutaneous VK2735 are enrolling ahead of schedule.</li></ul>Viking Therapeutics (VKTX) received a price target hike from Morgan Stanley on Thursday on the heels of positive third-quarter updates.&nbsp;Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating. The new price target represents a potential upside of 225% from the stock’s closing price on Wednesday.<h2 class="st-heading-2">Morgan Stanley’s Take</h2>The analyst noted that two of the company’s late-stage trials for subcutaneous VK2735 are enrolling ahead of schedule, and the management plans to meet with the U.S. Food and Drug Administration for oral VK2735 in Q4 with a late-stage study start targeted soon after. The firm is "encouraged by swift execution across programs," the analyst added.Viking CEO Brian Lian said on Thursday that the company is expected to complete enrollment in the VANQUISH-1 study later this quarter, with VANQUISH-2 to follow in the first quarter of 2026. The VANQUISH late-stage program, including trials of Viking's subcutaneous formulation of VK2735 in patients with obesity and obesity with type 2 diabetes, was initiated in the second quarter.Viking on Thursday <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update-302591893.html">reported</a> a third-quarter loss per share of $0.81, compared to the expected loss of $0.7 per share, according to data from Fiscal AI. The company pinned the rise in net loss for the three months ended Sept. 30, 2025, to the increase in research and development expenses.The company ended the quarter with a cash position of $715 million, which it believes provides sufficient resources to develop VK2735 through the VANQUISH clinical trials and to continue development of additional clinical programs in its pipeline.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/VKTX">VKTX shares</a> soared 7% at the time of writing. On Stocktwits, retail sentiment around VKTX jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels. Retail chatter around the stock rose 197% over the past 24 hours, as of Thursday morning, according to Stocktwits data.<figure class="image"><img style="aspect-ratio:620/63;" src="data:image/png;base64,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" width="620" height="63" alt="VKTX's Sentiment Meter and Message Volume as of 10:06 a.m. ET on Oct. 23, 2025 | Source: Stocktwits"><figcaption>VKTX's Sentiment Meter and Message Volume as of 10:06 a.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>VKTX stock is down by 16% this year and by 44% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-raises-full-year-revenue-guidance-ahead-of-earnings/cLG4ilnR3rG">Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Soars After Morgan Stanley’s Price Target Implies A Potential 225% Upside

Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating.

Buy, Hold and Build Wealth: ETFs for Long-Term Investors

Market volatility is rising but buy-and-hold ETFs like SPY, VOO and VTI offer investors diversification and long-term resilience.

Anavex Life Sciences (AVXL) on Thursday said that its investigational drug achieved its primary endpoint in a mid-stage trial and demonstrated safety and tolerability in adults with Schizophrenia.Shares of the company soared 9% in Thursday’s pre-market session.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160275/29248/en/Anavex-Life-Sciences-Announces-Positive-Topline-Results-from-Phase-2-Study-of-ANAVEX-3-71-for-the-Treatment-of-Schizophrenia.html">said</a> that the safety profile of ANAVEX3-71 was consistent with previous studies in healthy volunteers, and no serious treatment-emergent adverse events were reported in the study.The company is evaluating the drug in the treatment of Schizophrenia, a persistent and often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide. According to Anavex, the illness impacts 2.8 million people in the U.S. alone.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume stayed at ‘high’ levels.Anavex also said on Thursday that encouraging trends were observed in biomarkers of Schizophrenia in the study that support continued development. This includes a reduced glial fibrillary acidic protein in patients receiving ANAVEX3-71 compared to placebo.GFAP is a marker of neuroinflammation, and a reduction in it suggests a potential disease-modifying effect that may become more pronounced with longer treatment durations, the company said.The company on Thursday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160281/29248/en/Anavex-Life-Sciences-Announces-Successful-Development-of-Once-Daily-Oral-Tablet-Formulation-for-the-ANAVEX-3-71-Program.html">announced</a> the successful development of a once-daily oral tablet formulation for the ANAVEX3-71 program. The tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, enabling once-daily dosing, it added.AVXL stock is down 16% this year but up approximately 59% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-slashes-full-year-delivery-guidance-after-drop-in-q3-figures/chCrfpbR3OH">Rivian Slashes Full-Year Delivery Guidance After Drop In Q3 Figures</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update

The company said that its investigational drug for Schizophrenia achieved its primary endpoint in a mid-stage trial.

Enanta Pharmaceuticals (ENTA) on Monday announced that its mid-stage trial evaluating the efficacy and safety of Zelicapavir in outpatient adults with acute Respiratory Syncytial Virus (RSV) infection who are at high risk of complications failed to meet the primary endpoint.Shares of the company, however, rose 58% by Monday afternoon. Notably, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-its">stated</a> that a clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms was observed for Zelicapavir compared to placebo, with a benefit of 2.2 days for the overall efficacy population and 6.7 days for patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or aged 75 and older.A lower hospitalization rate was observed for patients treated with Zelicapavir compared to placebo, and Zelicapavir demonstrated a robust antiviral effect, it added.The study, however, failed in its primary endpoint of lowering the time to resolution of lower respiratory tract disease symptoms to mild. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ENTA">ENTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_1_22_50_PM_png_995d6b1542.webp" alt="ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="576" height="65"><figcaption>ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user cheered the rally.<stembedurl>https://stocktwits.com/JL_TradeZ/message/630342393</stembedurl>Another noted that though the trial missed the primary endpoint, the rest of the data “looks great.”<stembedurl>https://stocktwits.com/heyupikachu1821/message/630357384</stembedurl>Enanta said on Monday that Zelicapavir demonstrated a favorable safety profile in the trial and was well-tolerated. The goal of the study was to inform the design of a late-stage trial, including populations and endpoints, and no adverse events led to treatment discontinuation or study withdrawal in the Zelicapavir group.“We believe the totality of these data provides strong rationale for further clinical advancement of zelicapavir. Importantly, we identified multiple potential registrational endpoints for a Phase 3 trial,” said Chief Medical Officer Scott T. Rottinghaus.RSV is a common respiratory virus that infects the lungs and respiratory tract. Older adults are at significantly increased risk of severe illness due to the natural weakening of the immune system with age.ENTA stock has more than doubled this year and gained by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kala-bio-stock-plunges-after-experimental-drug-fails-study/chDuP3wR3Ja">Kala Bio Stock Just Plunged 89% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, capsules are seen in a hand dressed in a medical glove with the Enanta Pharmaceuticals logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.

uniQure N.V. (QURE) on Wednesday said that a high dose of its experimental gene therapy AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.Shares of the company rose a whopping 161% in the pre-market session at the time of writing.Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities, and cognitive decline. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.uniqure.com/investors-media/press-releases">stated</a> that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS), a comprehensive assessment tool used in clinical trials for Huntington's disease. The company also identified a statistically significant 60% slowing of disease progression as measured by Total Functional Capacity (TFC) at 36 months.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QURE">QURE stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.uniQure on Wednesday said that the therapy was generally well-tolerated in the trial with a manageable safety profile. No new drug-related serious adverse events have been observed from December 2022 to the end of June 2025, it added.Chief Medical Officer Walid Abi-Saab said that the company is looking forward to discussing the data with the U.S. Food and Drug Administration at a meeting later this year. The company plans to submit an application for approval of AMT-130 to the FDA in the first quarter of 2026 and anticipates launching it in the U.S. later in the same year.According to the company, there are currently no approved therapies to slow the progression of Huntington’s disease. The disease affects approximately 75,000 people in the U.S., EU, and the U.K., it added.QURE stock is down by 23% this year but has risen approximately 166% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-pharmaceuticals-investigational-drug-for-rare-genetic-disorder-fails-in-late-stage-study/chD1Gf0R33B">Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

QURE Stock Jumped A Whopping 161% Pre-Market – Here’s What Happened

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 

ETFs to Gain as Inflation Edges Higher in August

Inflation rose in August, but jobless claims rose, too, shaping Fed rate cut odds and boosting the appeal of large-cap blend ETFs like ITOT, EDOW and IVV. 

ITOT
iShares Core S&P Total U.S. Stock Market ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ITOT News

ITOTiShares Core S&P Total U.S. Stock Market ETF